Skip to main navigation Skip to search Skip to main content

Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography

  • Pharit Kamsri
  • , Chayanin Hanwarinroj
  • , Naruedon Phusi
  • , Thimpika Pornprom
  • , Kampanart Chayajarus
  • , Auradee Punkvang
  • , Nitima Suttipanta
  • , Potjanee Srimanote
  • , Khomson Suttisintong
  • , Chomphunuch Songsiriritthigul
  • , Patchreenart Saparpakorn
  • , Supa Hannongbua
  • , Siriluk Rattanabunyong
  • , Supaporn Seetaha
  • , Kiattawee Choowongkomon
  • , Sanya Sureram
  • , Prasat Kittakoop
  • , Poonpilas Hongmanee
  • , Pitak Santanirand
  • , Zhaoqiang Chen
  • Weiliang Zhu, Rosemary A. Blood, Yuiko Takebayashi, Philip Hinchliffe, Adrian J. Mulholland, James Spencer, Pornpan Pungpo
  • Nakhon Phanom University
  • Faculty of Science
  • Ubon Ratchathani University
  • Thammasat University
  • National Science and Technology Development Agency (NSTDA)
  • Synchrotron Light Research Institute (Public Organization)
  • Kasetsart University
  • Chulabhorn Research Institute
  • Chulabhorn Royal Academy
  • CHE
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • University of Bristol

Research output: Contribution to journal › Article › peer-review

56 Citations (Scopus)

Abstract

The enoyl-acyl carrier protein reductase InhA of Mycobacterium tuberculosis is an attractive, validated target for antituberculosis drug development. Moreover, direct inhibitors of InhA remain effective against InhA variants with mutations associated with isoniazid resistance, offering the potential for activity against MDR isolates. Here, structure-based virtual screening supported by biological assays was applied to identify novel InhA inhibitors as potential antituberculosis agents. High-speed Glide SP docking was initially performed against two conformations of InhA differing in the orientation of the active site Tyr158. The resulting hits were filtered for drug-likeness based on Lipinski's rule and avoidance of PAINS-like properties and finally subjected to Glide XP docking to improve accuracy. Sixteen compounds were identified and selected for in vitro biological assays, of which two (compounds 1 and 7) showed MIC of 12.5 and 25 μg/mL against M. tuberculosis H37Rv, respectively. Inhibition assays against purified recombinant InhA determined IC50 values for these compounds of 0.38 and 0.22 μM, respectively. A crystal structure of the most potent compound, compound 7, bound to InhA revealed the inhibitor to occupy a hydrophobic pocket implicated in binding the aliphatic portions of InhA substrates but distant from the NADH cofactor, i.e., in a site distinct from those occupied by the great majority of known InhA inhibitors. This compound provides an attractive starting template for ligand optimization aimed at discovery of new and effective compounds against M. tuberculosis that act by targeting InhA.

Original languageEnglish
Pages (from-to)226-234
Number of pages9
JournalJournal of Chemical Information and Modeling
Volume60
Issue number1
DOIs
Publication statusPublished - 27 Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography'. Together they form a unique fingerprint.

Cite this